Roundtable Renal Cell Carcinoma

Advertisement
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
Sequencing, novel therapies, and treatment combinations for refractory RCC are examined in part 5 of this discussion.
View More
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
The panel explores the evolving role of cytoreductive nephrectomy in RCC and how biomarkers shape treatment decisions.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
The panel discusses considerations for triplet therapy in RCC, new trial data, and biomarker-driven treatment strategies.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
In part 2, the panelists discuss adjuvant therapy for RCC, including biomarkers and optimizing treatment for better outcomes.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
Part one of the discussion covers adjuvant therapy in kidney cancer, patient selection, and balancing risks and benefits.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 23, 2024
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel shared their excitement for the road ahead in kidney cancer.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel discussed the impact of a subcutaneous formulation of nivolumab.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
Rana McKay, MDRenal Cell Carcinoma | May 31, 2024
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
Advertisement
Advertisement
Advertisement